PROCEPT BioRobotics Corp (PRCT) — SEC Financial Statements & Analysis

PROCEPT BioRobotics Corp (PRCT) is a surgical & medical instruments & apparatus company, incorporated in DE. PROCEPT BioRobotics Corp trades on Nasdaq as: PRCT. PROCEPT BioRobotics Corp (PRCT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, PROCEPT BioRobotics Corp carries a market cap of $1.29B, a P/E ratio of -11.74x, a P/B ratio of 3.79x, a P/S ratio of 3.82x, an enterprise value of $1.11B, and an EV/EBITDA multiple of -10.35x. On profitability, it posts a gross margin of 64.22%, an operating margin of -33.86%, a net margin of -32.54%, a Return on Equity (ROE) of -30.24%, a Return on Assets (ROA) of -22.12%, and a Return on Invested Capital (ROIC) of -74.99%. Per share, it reports EPS of $-1.92, diluted EPS of $-1.92, free cash flow per share of $-1.49, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 22.69% year-over-year, net income growth of 30.44% year-over-year, and EPS growth of 26.73% year-over-year. On the balance sheet, it maintains a current ratio of 6.55x, a quick ratio of 5.23x, working capital of $356.09M, a debt-to-equity ratio of 0.41x, a debt ratio of 0.29, an interest coverage ratio of -32.88x, free cash flow of $-84.92M (TTM), and net debt of $-179.24M. Figures sourced from SEC EDGAR.

Market Cap

$1.29B

P/E TTM

-11.74x

EPS TTM

$-1.92

P/B TTM

3.79x

ROE TTM

-30.24%

ROA TTM

-22.12%

Debt To Equity

0.41x

Free Cash Flow TTM

$-84.92M

Net Revenue TTM Growth 1Y

22.69%

Data as of 2026-06-30 · Source: SEC EDGAR